CoChat
Sign Up
Cited by 111

The DOI matches its Crossref record.

Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network

Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), Vuppalanchi, Raj, Gould, Robert J., Wilson, Laura A., Unalp-Arida, Aynur, Cummings, Oscar W., Chalasani, Naga, Kowdley, Kris V.·2012·Hepatology International
DOI 10.1007/s12072-011-9277-8PMC PMC3511661
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12072-011-9277-8

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98(5):960–967 · DOI
  2. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006;44(2):466–471 · DOI
  3. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8(3):521–33. viii · DOI
  4. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48(6):2086–2087 (author reply 2087) · DOI
  5. Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009;15(35):4387–4391 · DOI
  6. Anty R, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010;32(11–12):1315–1322 · DOI
  7. Angulo P, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846–854 · DOI
  8. Rosenberg WM, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127(6):1704–1713 · DOI
  9. Guha IN, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47(2):455–460 · DOI
  10. Ratziu V, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6 · DOI
  11. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004;99(7):1316–1320 · DOI
  12. Yatsuji S, et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the international autoimmune hepatitis group scoring system useful? J Gastroenterol 2005;40(12):1130–1138 · DOI
  13. Niwa H, et al. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol Res 2007;37(11):923–931 · DOI
  14. Bacon BR, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107(4):1103–1109 · DOI
  15. Caldwell SH, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29(3):664–659 · DOI
  16. Laroussi N, et al. Non alcoholic steatohepatitis: a multifactorial, frequent, paucysymptomatic liver disease with a fibrotic outcome. Gastroenterol Clin Biol 2002;26(5):475–479
  17. Cotler SJ, et al. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 2004;38(9):801–804 · DOI
  18. Loria P, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003;48(11):2173–2181 · DOI
  19. Loria P, Carulli N, Lonardo A. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease letters to the editor. Am J Gastroenterol 2005;5(100):1200–1201 · DOI
  20. Adams A, Angulo P. Insulin resistance, auto-antibodies, and nonalcoholic fatty liver disease, response to letter. Am J Gastroenterol 2005;100(5):1201–1202 · DOI
  21. Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2003;37:244. · DOI
  22. Chalasani NP, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009;30(1):88–96 · DOI
  23. Tan EM, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997;40(9):1601–1611 · DOI · Paper page
  24. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313–1321 · DOI · Paper page
  25. Syn WK, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010;51(6):1998–2007 · DOI · Paper page
  26. Naito T, et al. Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol 2002;129(3):397–404 · DOI
  27. Fujii Y et al. Co-appearance of autoantibody-producing B220(low) B cells with NKT cells in the course of hepatic injury. Cell Immunol 2010;260(2):105–112 · DOI
  28. Satoh M, Del Vazquez-Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009;19(3):219–228 · DOI
  29. Patton HM, et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008;135(6):1961e2–1971e2 · DOI

Cited by

Sorted by citations

Metadata

Authors
Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), Vuppalanchi, R., Gould, R. J., Wilson, L. A., Unalp-Arida, A., Cummings, O. W., Chalasani, N., & Kowdley, K. V.
Venue
Hepatology International
Publisher
Springer Science and Business Media LLC
Published
2011-05-10
Volume
6
Issue
1
Pages
379-385
ISSN
  • 1936-0533
  • 1936-0541
DOI
10.1007/s12072-011-9277-8
PMC
PMC3511661
Cited by
111
References
0
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review